Inhibikase Therapeutics, Inc. (IKT) KPIs and segments
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Inhibikase Therapeutics's business
Coming soon
This tab will track the numbers specific to Inhibikase Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?